Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAntibodies are indispensable instruments in research owing to their exceptional specificity, strong binding affinity, extended lifespans, and minimal toxicity. At Creative Biolabs, our top-tier hybridoma development services cater to a wide array of assay requirements including ELISA, western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF), fluorescence-activated cell sorting (FACS), and beyond. We offer customized and adaptable solutions tailored precisely to meet your unique needs.
Developing antibodies with guaranteed functionality across diverse detection methods requires careful consideration of antigen presentation and antibody specificity. The accessibility of the epitope, the specific region on the antigen recognized by the antibody, is paramount for effective binding. Various treatments during sample preparation, such as pH changes, fixation, or denaturation, can alter the epitope's conformation, potentially hindering antibody recognition. Consequently, an antibody might perform well in one application, like IHC, where the antigen retains a more native structure, but poorly in another, such as WB, where proteins are denatured. Antibodies generated against native protein structures are more likely to excel in assays utilizing non-denatured proteins, such as IP or FACS. Conversely, antibodies raised against denatured proteins often show superior performance in applications involving denatured antigens, like WB. Therefore, a function-guaranteed approach necessitates tailoring the antibody development process to the intended application, ensuring optimal epitope recognition under the specific assay conditions to reliably meet various detection needs.
At Creative Biolabs, we offer customized services, and our Function-Guaranteed Antibody Development Services follow a meticulous workflow designed to deliver optimal results.
Initially, we engage in detailed consultations with our clients to thoroughly understand their project objectives, target antigens, and intended antibody applications. A critical aspect of this phase involves the design of tailored functional assays. These assays are specifically designed to evaluate the ability of generated antibodies to elicit the desired biological response, reflecting the client's specific experimental needs.
Subsequently, we employ optimized protocols for antigen preparation to ensure the generation of high-quality antibodies. This may involve recombinant protein expression, peptide synthesis, or cell-based antigen preparation, depending on the nature of the target. Following antigen preparation, we proceed with immunizing host animals using carefully selected immunization strategies and adjuvants to maximize the immune response against the target antigen.
Hybridoma technology serves as a cornerstone in our workflow, allowing for the generation of monoclonal antibodies with exceptional specificity. After successful immunization, we fuse spleen cells from immunized animals with myeloma cells to create hybridomas. The resulting hybridoma cells are then subjected to a rigorous screening process.
A key differentiator of our service lies in the application-specific screening phase. In this step, hybridoma supernatants are screened using the functional assays developed during the initial consultation. This ensures that only antibodies demonstrating the desired biological activity in the client's intended application are selected for further development. For instance, if the antibody is intended for use in flow cytometry, we screen for FACS-positive clones.
Following functional screening, we perform a comprehensive characterization of the selected antibody candidates. This typically includes assessments of binding affinity, specificity, and cross-reactivity. Furthermore, we conduct rigorous validation assays to confirm the antibody's performance in the client's target application, providing further assurance of its suitability.
We then expand the hybridoma clones that have passed all screening and characterization steps. These expanded clones are used for antibody production. We employ robust cell culture methods to generate sufficient quantities of high-quality antibodies to meet our clients' research or development needs.
Finally, we deliver the purified antibodies to our clients, along with comprehensive data packages detailing the antibody's characteristics and performance in the functional assays. Our commitment extends beyond delivery, as we provide ongoing technical support and consultation to ensure client success in their downstream applications.
Antibodies in research identify proteins intracellularly and extracellularly. We differentiate cell types in FACS, detect proteins in WB, and isolate proteins in IP. Also, we analyze protein expression in tissue sections or localize proteins within cells in IHC or IF. ELISA quantifies proteins using antibodies. Considering varied applications, it's crucial to align hybridoma screening methods with intended uses. Creative Biolabs offers function-guaranteed hybridoma development services tailored to diverse research needs.
Fig.1 Illustration of the chemiluminescent screening of specific hybridoma cells with proximity-rolling circle activated enzymatic switch.1
Aiming to establish an efficient, straightforward, versatile, and economical screening system, Ao, Hang, et al. introduced a chemiluminescent protocol specifically tailored for identifying specific hybridoma cells using standard 96-well plates1. This approach involves distributing heterogeneous hybridoma cells into the wells of a 96-well plate through limiting dilution, ensuring that each well contains only a single cell. After a one-day incubation period, during which the target antibody is secreted by the specific hybridoma cells without any proliferation, a chemiluminescent assay is performed on the supernatant of each hybridoma cell to detect and screen for the desired antibody production. Notably, this screening method utilizes a proximity-rolling circle activated enzymatic switch to evaluate the secreted PCSK9-Ab (antibody targeting PCSK9) via chemiluminescent analysis, thereby pinpointing the specific hybridoma cells of interest.
A: The term "function-guaranteed" signifies our commitment to delivering antibodies that not only bind to your target antigen but also perform the specific testing function you require in your application. We work closely with you during the initial consultation to define the criteria for functionality, and we design our screening process to ensure that the selected antibodies meet these criteria. This guarantee minimizes the risk of receiving antibodies that are unsuitable for your intended use.
A: Our primary technology for this service is hybridoma technology, a well-established method for generating monoclonal antibodies with high specificity. We leverage our expertise in hybridoma generation to create stable and high-producing cell lines.
A: Antibody specificity is a critical parameter, and we employ several strategies to ensure high specificity. During the screening process, we utilize rigorous selection methods to identify clones that exhibit minimal cross-reactivity with off-target antigens. We also perform thorough characterization of the final antibody product, including specificity assays and cross-reactivity testing, to validate its binding profile.
A: We believe in close collaboration with our clients and ensure that you have control over key aspects of the project. You will be involved in the initial consultation, assay design, and review of data at critical decision points. We appreciate your feedback and strive to align our efforts with your specific needs and preferences.
A: Yes, we offer a range of antibody engineering services to enhance the properties of the antibodies generated, including affinity maturation, humanization, and Fc engineering. These services can improve the antibody's binding affinity, reduce immunogenicity, and enhance its effector functions, respectively. We can tailor these engineering strategies to meet the unique needs of your downstream applications.
With a wealth of expertise in mAb production, Creative Biolabs is acknowledged as a frontrunner in this domain. Bolstered by our cutting-edge hybridoma facilities, we ensure the provision of a wide array of hybridoma-related services. We eagerly await your to contact us for additional information.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
